These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22626984)

  • 21. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
    Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
    Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
    Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
    Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
    van de Loosdrecht AA; Alhan C; Béné MC; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Homburg CH; Ireland R; Jansen JH; Kern W; Malcovati L; Te Marvelde JG; Mufti GJ; Ogata K; Orfao A; Ossenkoppele GJ; Porwit A; Preijers FW; Richards SJ; Schuurhuis GJ; Subirá D; Valent P; van der Velden VH; Vyas P; Westra AH; de Witte TM; Wells DA; Loken MR; Westers TM
    Haematologica; 2009 Aug; 94(8):1124-34. PubMed ID: 19546437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic utility of the lymphoid screening tube supplemented with CD34 for Ogata score calculation in patients with peripheral cytopenia.
    Muyldermans A; Florin L; Devos H; Cauwelier B; Emmerechts J
    Hematology; 2019 Dec; 24(1):166-172. PubMed ID: 30334700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes.
    Maftoun-Banankhah S; Maleki A; Karandikar NJ; Arbini AA; Fuda FS; Wang HY; Chen W
    Am J Clin Pathol; 2008 Feb; 129(2):300-8. PubMed ID: 18208811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
    Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
    Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
    Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
    Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
    Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
    Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes.
    Davydova YO; Parovichnikova EN; Galtseva IV; Kokhno AV; Dvirnyk VN; Kovrigina AM; Obukhova TN; Kapranov NM; Nikiforova KA; Glinkina SA; Troitskaya VV; Mikhailova EA; Fidarova ZT; Moiseeva TN; Lukina EA; Tsvetaeva NV; Nikulina OF; Kuzmina LA; Savchenko VG
    Cytometry B Clin Cytom; 2021 May; 100(3):312-321. PubMed ID: 33052634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
    Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
    Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of myelodysplastic syndromes in cytopenic patients.
    Wang SA
    Hematol Oncol Clin North Am; 2011 Oct; 25(5):1085-110, vii. PubMed ID: 22054736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
    Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
    Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
    van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
    Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.
    Della Porta MG; Picone C; Pascutto C; Malcovati L; Tamura H; Handa H; Czader M; Freeman S; Vyas P; Porwit A; Saft L; Westers TM; Alhan C; Cali C; van de Loosdrecht AA; Ogata K
    Haematologica; 2012 Aug; 97(8):1209-17. PubMed ID: 22315489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells.
    Sawada K; Sato N; Notoya A; Tarumi T; Hirayama S; Takano H; Koizumi K; Yasukouchi T; Yamaguchi M; Koike T
    Blood; 1995 Jan; 85(1):194-202. PubMed ID: 7528567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophenotypic clustering of myelodysplastic syndromes.
    Maynadié M; Picard F; Husson B; Chatelain B; Cornet Y; Le Roux G; Campos L; Dromelet A; Lepelley P; Jouault H; Imbert M; Rosenwadj M; Vergé V; Bissières P; Raphaël M; Béné MC; Feuillard J;
    Blood; 2002 Oct; 100(7):2349-56. PubMed ID: 12239142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.
    Florian S; Sonneck K; Hauswirth AW; Krauth MT; Schernthaner GH; Sperr WR; Valent P
    Leuk Lymphoma; 2006 Feb; 47(2):207-22. PubMed ID: 16321850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of a Blast Dominance-Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS).
    Schenkel JM; Hergott CB; Dudley G; Drew M; Charest K; Dorfman DM
    Am J Clin Pathol; 2019 May; 151(6):584-592. PubMed ID: 30854558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.
    Aalbers AM; van den Heuvel-Eibrink MM; Baumann I; Dworzak M; Hasle H; Locatelli F; De Moerloose B; Schmugge M; Mejstrikova E; Nováková M; Zecca M; Zwaan CM; Te Marvelde JG; Langerak AW; van Dongen JJ; Pieters R; Niemeyer CM; van der Velden VH
    Haematologica; 2015 Mar; 100(3):315-23. PubMed ID: 25425683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.